Hepatic cytochrome P450s attenuate the cytotoxicity induced by leflunomide and its active metabolite A77 1726 in primary cultured rat hepatocytes

Toxicological Sciences

Volumn 122, Issue 2, 2011, Pages 579-586

  Shi, Qiang ^a   Yang, Xi ^a   Greenhaw, James ^a   Salminen, William F ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

A77 1726; Cytochrome P450s; Hepatocytes; Hepatotoxicity; Leflunomide; Rat

Indexed keywords

1 AMINOBENZOTRIAZOLE; ALPHA NAPHTHOFLAVONE; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 2B; CYTOCHROME P450 2C; CYTOCHROME P450 3A; DEXAMETHASONE; ISOENZYME; KETOCONAZOLE; LACTATE DEHYDROGENASE; LEFLUNOMIDE; METYRAPONE; PROADIFEN; TERIFLUNOMIDE; TICLOPIDINE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DETOXIFICATION; DRUG POTENTIATION; ENZYME INDUCTION; ENZYME INHIBITION; LIVER TOXICITY; MALE; METABOLIC ACTIVATION; NONHUMAN; PROTEIN TARGETING; RAT;

ANILINE COMPOUNDS; ANIMALS; BENZOFLAVONES; BIOLOGICAL MARKERS; CELL SURVIVAL; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; HEPATOCYTES; HYDROXYBUTYRATES; ISOXAZOLES; KETOCONAZOLE; LIVER; MALE; METABOLIC DETOXICATION, DRUG; PRIMARY CELL CULTURE; PROADIFEN; RATS; RATS, SPRAGUE-DAWLEY; TICLOPIDINE; TRIAZOLES;

RATTUS;

EID: 80051674638     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr106     Document Type: Article

References (35)

1. Alcorn, N., Saunders, S., and Madhok, R. (2009). Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf. 32, 1123-1134.
2. Bertele, V., Assisi, A., Di Muzio, V., Renzo, D., and Garattini, S. (2007). New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval. Eur. J. Clin. Pharmacol. 63, 879-889.
3. Bohanec Grabar, P., Rozman, B., Tomsic, M., Suput, D., Logar, D., and Dolzan, V. (2008). Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur. J. Clin. Pharmacol. 64, 871-876.
4. Breedveld, F. C. (2001). Is there a place for leflunomide in the treatment of rheumatoid arthritis? Lancet. 358, 1198-1200.
5. Breedveld, F. C., and Dayer, J. M. (2000). Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 59, 841-849.
6. Chan, E. C., and New, L. S. (2007). In vitro metabolism of leflunomide by mouse and human liver microsomes. Drug Metab. Lett. 1, 299-305.
7. Chao, E. S., Dunbar, D., and Kaminsky, L. S. (1988). Intracellular lactate dehydrogenase concentration as an index of cytotoxicity in rat hepatocyte primary culture. Cell Biol. Toxicol. 4, 1-11.
8. Hewitt, N. J., Lechon, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007). Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev. 39, 159-234.
9. Ishihara, Y., Shiba, D., and Shimamoto, N. (2006). Enhancement of DMNQinduced hepatocyte toxicity by cytochrome P450 inhibition. Toxicol. Appl. Pharmacol. 214, 109-117.
10. Jurima-Romet, M., Huang, H. S., Paul, C. J., and Thomas, B. H. (1991). Enalapril cytotoxicity in primary cultures of rat hepatocytes. I. Effects of cytochrome P450 inducers and inhibitors. Toxicol. Lett. 58, 257-267.
11. Kalgutkar, A. S., Nguyen, H. T., Vaz, A. D., Doan, A., Dalvie, D. K., McLeod, D. G., and Murray, J. C. (2003). In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab. Dispos. 31, 1240-1250.
12. Karaman, A., Fadillioglu, E., Turkmen, E., Tas, E., and Yilmaz, Z. (2006). Protective effects of leflunomide against ischemia-reperfusion injury of the rat liver. Pediatr. Surg. Int. 22, 428-434.
13. Kostrubsky, S. E., Strom, S. C., Kalgutkar, A. S., Kulkarni, S., Atherton, J., Mireles, R., Feng, B., Kubik, R., Hanson, J., Urda, E., et al. (2006). Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 90, 451-459.
14. Lammert, C., Bjornsson, E., Niklasson, A., and Chalasani, N. (2010). Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology. 51, 615-620.
15. Latchoumycandane, C., Goh, C. W., Ong, M. M., and Boelsterli, U. A. (2007). Mitochondrial protection by the JNK inhibitor leflunomide rescues mice from acetaminophen-induced liver injury. Hepatology. 45, 412-421.
16. Latchoumycandane, C., Seah, Q. M., Tan, R. C., Sattabongkot, J., Beerheide, W., and Boelsterli, U. A. (2006). Leflunomide or A77 1726 protect from acetaminophen-induced cell injury through inhibition of JNKmediated mitochondrial permeability transition in immortalized human hepatocytes. Toxicol. Appl. Pharmacol. 217, 125-133.
17. Legras, A., Bergemer-Fouquet, A. M., and Jonville-Bera, A. P. (2002). Fatal hepatitis with leflunomide and itraconazole. Am. J. Med. 113, 352-353.
18. Lim, P. L., Tan, W., Latchoumycandane, C., Mok, W. C., Khoo, Y. M., Lee, H. S., Sattabongkot, J., Beerheide, W., Lim, S. G., Tan, T. M., et al. (2007). Molecular and functional characterization of drug-metabolizing enzymes and transporter expression in the novel spontaneously immortalized human hepatocyte line HC-04. Toxicol. In Vitro. 21, 1390-1401.
19. Linder, C. D., Renaud, N. A., and Hutzler, J. M. (2009). Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab. Dispos. 37, 10-13.
20. Martignoni, M., Groothuis, G. M., and de Kanter, R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert. Opin. Drug Metab. Toxicol. 2, 875-894.
21. Migita, K., Miyashita, T., Maeda, Y., Nakamura, M., Yatsuhashi, H., Ishibashi, H., and Eguchi, K. (2005). An active metabolite of leflunomide, A77 1726, inhibits the production of serum amyloid A protein in human hepatocytes. Rheumatology (Oxford). 44, 443-448.
22. Moynihan, R. (2003). FDA officials argue over safety of new arthritis drug. BMJ. 326, 565.
23. Nishimura, M., Koeda, A., Suganuma, Y., Suzuki, E., Shimizu, T., Nakayama, M., Satoh, T., Narimatsu, S., and Naito, S. (2007). Comparison of inducibility of CYP1A and CYP3A mRNAs by prototypical inducers in primary cultures of human, cynomolgus monkey, and rat hepatocytes. Drug Metab. Pharmacokinet. 22, 178-186.
24. Roberts, R. A., Ganey, P. E., Ju, C., Kamendulis, L. M., Rusyn, I., and Klaunig, J. E. (2007). Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol. Sci. 96, 2-15.
25. Rozman, B. (2002). Clinical pharmacokinetics of leflunomide. Clin. Pharmacokinet. 41, 421-430.
26. Seah, Q. M., New, L. S., Chan, E. C., and Boelsterli, U. A. (2008). Oxidative bioactivation and toxicity of leflunomide in immortalized human hepatocytes and kinetics of the non-enzymatic conversion to its major metabolite, A77 1726. Drug Metab. Lett. 2, 153-157.
27. Seglen, P. O. (1972). Preparation of rat liver cells. I. Effect of Ca 2+ on enzymatic dispersion of isolated, perfused liver. Exp. Cell Res. 74, 450-454.
28. Sevilla-Mantilla, C., Ortega, L., Agundez, J. A., Fernandez-Gutierrez, B., Ladero, J. M., and Diaz-Rubio, M. (2004). Leflunomide-induced acute hepatitis. Dig. Liver Dis. 36, 82-84.
29. Tan, S. C., New, L. S., and Chan, E. C. (2008). Prevention of acetaminophen (APAP)-induced hepatotoxicity by leflunomide via inhibition of APAP biotransformation to N-acetyl-p-benzoquinone imine. Toxicol. Lett. 180, 174-181.
30. van Roon, E. N., Jansen, T. L., van de Laar, M. A., Janssen, M., Yska, J. P., Keuper, R., Houtman, P. M., and Brouwers, J. R. (2005). Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64, 569-574.
31. Vernia, S., Beaune, P., Coloma, J., and Lopez-Garcia, M. P. (2001). Differential sensitivity of rat hepatocyte CYP isoforms to self-generated nitric oxide. FEBS Lett. 488, 59-63.
32. Vrenken, T. E., Buist-Homan, M., Kalsbeek, A. J., Faber, K. N., and Moshage, H. (2008). The active metabolite of leflunomide, A77 1726, protects rat hepatocytes against bile acid-induced apoptosis. J. Hepatol. 49, 799-809.
33. Walgren, J. L., Mitchell, M. D., and Thompson, D. C. (2005). Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 35, 325-361.
34. Wright, M. C., Paine, A. J., Skett, P., and Auld, R. (1994). Induction of rat hepatic glucocorticoid-inducible cytochrome P450 3A by metyrapone. J. Steroid Biochem. Mol. Biol. 48, 271-276.
35. Zaher, H., Buters, J. T., Ward, J. M., Bruno, M. K., Lucas, A. M., Stern, S. T., Cohen, S. D., and Gonzalez, F. J. (1998). Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Toxicol. Appl. Pharmacol. 152, 193-199.